Market Research Logo

Hereditary Angioedema Market, by Drug Class, Route of Administration, Distribution Channel, and Region - Global Trends and Forecast till 2025

Hereditary Angioedema Market, by Drug Class, Route of Administration, Distribution Channel, and Region - Global Trends and Forecast till 2025

Hereditary angioedema (HAE) is characterized by acute skin and mucosal edema caused by an autosomal dominant mutation of the genes. The current treatments of the condition include the HAE drugs which can be administered intravenously, subcutaneously or taken orally. The disease causes swelling particularly of the face and airways and abdominal cramping. The World Allergy Organization (WAO) has set out guidelines to use the different class of drugs such as esterase inhibitors, kallikrein inhibitors and other drugs approved to treat hereditary angioedema.
Market Dynamics
The major factor driving growth of the hereditary angioedema market include intense R&D initiatives by the manufacturers to treat the condition, increasing prevalence of hereditary angioedema and the presence of promising drug pipeline. For instance, in 2017, Attune Pharmaceuticals, revealed the successful study results the first preclinical data results for ATN-249, a novel orally administered plasma kallikrein inhibitor for the treatment of Hereditary Angioedema (HAE). Also, the approval of novel therapies by the regulatory agencies is expected to be a factor augmenting market growth. For instance, in 2014, the FDA approved Ruconest manufactured by Pharming Healthcare, a recombinant C1-esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with HAE. However, lack of awareness regarding the diseases, inefficient diagnosis and high cost of drugs are the factors restraining hereditary angioedema market growth.
Key features of the study:

This report provides in-depth analysis of hereditary angioedema market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global hereditary angioedema market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include CSL Behring, Shire Plc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Adverum Biotechnologies, Attune Pharmaceuticals and Pharming Healthcare, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology upgrade, market expansion, and marketing tactics
The global hereditary angioedema market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pet cancer therapeutics market

Detailed Segmentation:

Global Hereditary Angioedema Market, By Drug Class:

C1 Esterase Inhibitor
Kallikrein Inhibitor
Bradykinin Receptor
Attenuated Androgens
Others

Global Hereditary Angioedema Market, By Route of Administration:

Subcutaneous
Intravenous
Oral

Global Hereditary Angioedema Market, By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
e-Commerce

Global Hereditary Angioedema Market, By Geography:

North America

By Drug Class:

C1 Esterase Inhibitor
Kallikrein Inhibitor
Bradykinin Receptor
Attenuated Androgens
Others

By Route of Administration:

Subcutaneous
Intravenous
Oral

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
e-Commerce

By Country:

U.S.
Canada

Latin America

By Drug Class:

C1 Esterase Inhibitor
Kallikrein Inhibitor
Bradykinin Receptor
Attenuated Androgens
Others

By Route of Administration:

Subcutaneous
Intravenous
Oral

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
e-Commerce

By Country:

Brazil
Mexico
Argentina
Rest of Latin America

Europe

By Drug Class:

C1 Esterase Inhibitor
Kallikrein Inhibitor
Bradykinin Receptor
Attenuated Androgens
Others

By Route of Administration:

Subcutaneous
Intravenous
Oral

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
e-Commerce

By Country:

Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe

Asia Pacific

By Drug Class:

C1 Esterase Inhibitor
Kallikrein Inhibitor
Bradykinin Receptor
Attenuated Androgens
Others

By Route of Administration:

Subcutaneous
Intravenous
Oral

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
e-Commerce

By Country:

China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific

Middle East

By Drug Class:

C1 Esterase Inhibitor
Kallikrein Inhibitor
Bradykinin Receptor
Attenuated Androgens
Others

By Route of Administration:

Subcutaneous
Intravenous
Oral

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
e-Commerce

By Country:

GCC
Israel
Rest of Middle East

Africa

By Drug Class:

C1 Esterase Inhibitor
Kallikrein Inhibitor
Bradykinin Receptor
Attenuated Androgens
Others

By Route of Administration:

Subcutaneous
Intravenous
Oral

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
e-Commerce

By Country:

South Africa
Central Africa
North Africa

Company Profiles

CSL Behring*

Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments

Shire Plc.
Pharming Healthcare, Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Attune Pharmaceuticals, Inc.

“*” marked represents similar segmentation in other categories in the respective section.


1. Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Drug Class
Market Snippet, By Route of Administration
Market Snippet, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Key Highlights
Pipeline Analysis
Regulatory Guidelines
Epidemiology
4. Global Hereditary Angioedema Market, By Drug Class, 2017 – 2025, (US$ Million)
Introduction
Market Share Analysis, 2016 and 2025 (%)
Y-o-Y Growth Analysis, 2017 – 2025
Segment Trends
C1 Esterase Inhibitor
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
Kallikrein Inhibitor
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
Bradykinin Receptor
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
Attenuated Androgens
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
5. Global Hereditary Angioedema Market, By Route of Administration, 2017 – 2025, (US$ Million)
Introduction
Market Share Analysis, 2016 and 2025 (%)
Y-o-Y Growth Analysis, 2017 – 2025
Segment Trends
Subcutaneous
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
Intravenous
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
6. Global Hereditary Angioedema Market, By Distribution Channel, 2017 – 2025, (US$ Million)
Introduction
Market Share Analysis, 2016 and 2025 (%)
Y-o-Y Growth Analysis, 2017 – 2025
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
e-Commerce
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
7. Global Hereditary Angioedema Market, By Region, 2017 – 2025, (US$ Million)
Introduction
Market Share Analysis, By Region, 2016 and 2025 (%)
Y-o-Y Growth Analysis, For Regions, 2017 – 2025
North America
Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
U.S.
Canada
Latin America
Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
China
India
Japan
Australia
South Korea
ASEAN
Rest of APAC
Middle East
Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
South Africa
Central Africa
North Africa
8. Competitive Landscape
Heat Map Analysis
Market Share Analysis (3x3 Matrix)
Company Profiles
CSL Behring*
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Shire Plc.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Pharming Healthcare, Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
BioCryst Pharmaceuticals, Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Ionis Pharmaceuticals, Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Attune Pharmaceuticals, Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Arrowhead Pharmaceuticals
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Adverum Biotechnologies
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Analyst Views
9. Section
References
Research Methodology
About us and Sales Contact
*Browse 58 market data tables and 32 figures on "Hereditary Angioedema Market - Global forecast to 2025”.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report